読み込み中
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
前日終値
$1.86
+$0.15 · +8.77%
日中の時刻はETです。市場データは遅延する場合があります。
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
日中レンジ
現在 $1.86
52週レンジ
現在 $1.86
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
44
適正価値
センチメント
54
まちまち
リスク
74
高リスク
モメンタム
55
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
日中レンジ
現在 $1.86
52週レンジ
現在 $1.86
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | — | 53.49万 USD | 51.67万 USD | 9.86万 USD | 4.25万 USD |
| 粗利益 | — | −53.49万 USD | −51.67万 USD | −9.86万 USD | −4.25万 USD |
| 研究開発 | 1342.18万 USD | 961.55万 USD | 1226.35万 USD | 1023.24万 USD | 275.4万 USD |
| 販売・一般管理 | 577.11万 USD | 551.04万 USD | 663.82万 USD | 833.48万 USD | 335.47万 USD |
| 営業費用 | 2798.01万 USD | 1512.58万 USD | 1890.18万 USD | 1856.72万 USD | 610.87万 USD |
| 受取利息 | 7.92万 USD | 684 USD | 5285 USD | 2.04万 USD | 664 USD |
| 支払利息 | 6616 USD | 2.68万 USD | 5.59万 USD | 1756.5万 USD | 9.51万 USD |
| 減価償却費と償却費 | 11.42万 USD | 53.49万 USD | 51.67万 USD | 9.86万 USD | 4.25万 USD |
| 営業利益 | −2798.01万 USD | −1566.07万 USD | −1941.85万 USD | −1866.58万 USD | −615.11万 USD |
| 純利益 | −3466.11万 USD | −1675.5万 USD | −1854.61万 USD | −1756.5万 USD | −684.34万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
